USPTO serial 99225625
XEED
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PATEL, SHEENA KAPOOR
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with XEED?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA, US
San Diego, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gina L. Durham
Gina L. Durham DLA Piper LLP (US)555 Mission Street, Suite 2400San Francisco, CA 94105-2933United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes and other extra-cellular vesicles for use in disease detection, namely, autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; medical diagnostic reagents and assays for testing of exosomes and other extra-cellular vesicles in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders | ACTIVE | — |
| 010 | Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; medical diagnostic apparatus for detecting autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; medical diagnostic apparatus, namely, lab-on-a-chip systems comprised of microelectrode arrays and microfluidic controllers, pumps, and valves for use in biological analysis; apparatus for carrying out diagnostic cell-based testing for medical purposes; diagnostic apparatus for autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders, namely, medical diagnostic apparatus for testing cell-derived vesicles or extra-cellular vesicles and detecting autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the field of oncology; medical diagnostic apparatus for detecting cancer; diagnostic apparatus for cancer diseases, namely, medical diagnostic apparatus for testing cell-derived vesicles or extra-cellular vesicles and detecting cancer; none of the foregoing comprising wearable movement tracking devices. | ACTIVE | — |
| 044 | Medical testing for diagnostic and treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Xzom, Inc.
- Other trademarks owned by Xzom, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named XEED
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 16, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 16, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 10, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 20, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 27, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 27, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 27, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 30, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 29, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jan 29, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Oct 30, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 15, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 9, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 9, 2025 | NWAP | NEW APPLICATION ENTERED | — |